-
In the past few years, Hispanics have become the largest minority group in the United States, numbering nearly 41.3 million in the most recent U.S. Census estimates.
-
Only 75% of patients that begin clinical trials for drugs fully complete, according to a recent study by Cutting Edge Information in Research Triangle Park, NC, noting several reasons for this low completion rate.
-
Physicians discussing clinical trials with their patients may not realize the importance of patients fears about side effects in making a decision about whether to participate.
-
The cost of operating institutional review boards is higher than previous estimates had indicated, according to a survey published recently in the New England Journal of Medicine.
-
What can IRBs do to help reach out to the Hispanic population in their own communities?
-
Protecting the identities and sensitive information of study subjects is one of the top priorities in research, particularly if a study involves topics that could be damaging to a subjects reputation.
-
For decades, IRBs and ethics panels have lamented the sorry state of informed consent documents.
-
The transition from a paper IRB submission process to an electronic one can be a long and, at times, frustrating journey. The key is to break goals into phases and deal with obstacles as they arise, an expert says.
-
IRBs continually struggle to find nonaffiliated and nonscientist volunteers to fill the challenging role of IRB member.
-
Biorepositories of tissue and blood samples are valuable resources for disease research. When developing the framework for a biorepository, IRBs and researchers must find the right balance of policies and procedures to fit the needs of the institution, ensure patient confidentiality, and fulfill regulatory requirements.